Matthew Charles joined DiaMedica in April 2009 where he is responsible for the development, manufacturing and preclinical programs for DM-199 and DM-204. Prior to DiaMedica, Mr. Charles was employed by Sanomune Inc., where he managed product development projects and intellectual property. Previous to this appointment he worked at CentreStone Ventures, a life sciences venture fund, where he evaluated technology investments including pharmaceutical compounds and medical devices.  Mr. Charles successfully completed the Westlink Technology Commercialization Internship Program and was employed at the University-Industry Liaison Office at the University of British Columbia.  He earned his Masters degree in Immunology and Microbiology from the University of Western Ontario.